Effect of thymosin alpha 1 on the antitumor activity of tumor-associated macrophage-derived dendritic cells

Journal of Biomedical Science

Volumn 11, Issue 5, 2004, Pages 623-630

  Shrivastava, Pratima ^a   Singh, Sukh Mahendra ^a   Singh, Nisha ^a  

^a BANARAS HINDU UNIVERSITY   (India)

Author keywords

Adoptive transfer; Cytotoxicity; Dalton's lymphoma; Dendritic cells; Interleukin 1; Nitric oxide; Thymosin 1; Tumor necrosis factor; Tumor associated macrophages

Indexed keywords

CYTOKINE; GRANULOCYTE COLONY STIMULATING FACTOR; INTERLEUKIN 1; INTERLEUKIN 4; THYMOSIN ALPHA1; TUMOR NECROSIS FACTOR;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; CONTROLLED STUDY; DENDRITIC CELL; DRUG EFFECT; FEMALE; IMMUNE DEFICIENCY; IMMUNOTHERAPY; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; STATISTICAL SIGNIFICANCE; SURVIVAL TIME; TUMOR ASSOCIATED LEUKOCYTE; TUMOR DIFFERENTIATION; TUMOR GROWTH;

ANIMALS; CYTOTOXICITY, IMMUNOLOGIC; DENDRITIC CELLS; FEMALE; GRANULOCYTE-MACROPHAGE COLONY-STIMULATING FACTOR; INTERLEUKIN-4; LYMPHOCYTE ACTIVATION; MACROPHAGES; MALE; MICE; MICE, INBRED BALB C; MICE, INBRED C3H; NEOPLASMS, EXPERIMENTAL; NITRITES; PINOCYTOSIS; T-LYMPHOCYTES; THYMOSIN; TUMOR CELLS, CULTURED; TUMOR NECROSIS FACTOR-ALPHA;

MURINAE;

EID: 4444379257     PISSN: 10217770     EISSN: 14230127     Source Type: Journal    
DOI: 10.1159/000079675     Document Type: Article

References (43)

1. Ancell CD, Phipps J, Young L. Thymosin alpha-1. Am J Health Syst Pharm 15:879-885;2001.
2. Banchereau J, Briere F, Caux C, Davoust J, Lebecque S, Liu YJ, Pulendran B, Palucka K. Immunobiology of dendritic cells. Annu Rev Immunol 18:767-81;2000.
3. Baumann C, Badamachian M, Goldstein A. Preclinical studies of thymosin α1 and thymosin β4. In: Maurer HR, Goldstein AL, Hager ED, eds. Thymic Peptides in Preclinical and Clinical Medicine - An Update. Munich, Zuckschwerdt, 13-27;1998.
4. Bell D, Chomarat P, Broyles D, Netto G, Harb GM, Lebecque S, Valladeau J, Davoust J, Palucka KA, Banchereau J. In breast carcinoma tissue, immature dendritic cells reside within the tumor, whereas mature dendritic cells are located in peritumoral areas. J Exp Med 190:1417-1425;1999.
5. Beuth J, Schierholz JM, Mayer G. Thymosin alpha-1 application augments immune response and down-regulates tumor weight and organ colonization in BALB/c-mice. Cancer Lett 159:9-13;2000.
6. Bharti A, Singh SM. Inhibition of macrophage nitric oxide production by gangliosides derived from a spontaneous T cell lymphoma: the involved mechanisms. Nitric Oxide 8:75-82;2003.
7. Billich A. Thymosin alpha1. SciClone Pharmaceuticals (review). Curr Opin Investig Drugs 3:698-707;2002.
8. Biragyn A, Ruffini PA, Leifer CA, Klyushnenkova E, Shakhov A, Chertov O, Shirakawa AK, Farber JM, Segal DM, Oppenheim JJ, Kwak LW. Toll-like receptor 4-dependent activation of dendritic cells by beta-defensin 2. Science 298:1025-1029;2002.
9. Bodey B, Bodey B Jr, Sigel SE, Kaiser HE. Review of thymic hormones in cancer diagnosis and treatment. Int J Immunopharmacol 22:261-273;2000.
10. Boudaly S, Morin J, Berthier R, Marche P, Boitard C. Altered dendritic cells (DC) might be responsible for regulatory T cell imbalance and autoimmunity in nonobese diabetic (NOD) mice. Eur Cytokine Network 13:29-37;2002.
11. Bubenik J. Genetically engineered dendritic cell-based cancer vaccines. Int J Oncol 18:475-478:2000.
12. Candido KA, Shimizu K, McLaughlin JC, et al. Local administration of dendritic cells inhibits established breast tumor growth: implications for apoptosis-inducing agents. Cancer Res 61:228-236;2001.
13. Chu CS, Woo EY, Toll AJ, Rubin SC, June CH, Caroll RG, Schlienger K. Tumor-associated macrophages as a source of functional dendritic cells in ovarian cancer patients. Clin Immunol 102:291-301;2002.
14. Colaco CA. Why are dendritic cells central to cancer immunotherapy. Mol Med Today 5:14-17;1999.
15. Garaci E, Pica F, Rasi G, Favalli C. Thymosin α1 in the treatment of cancer: from basic research to clinical application (review). Int J Immunopharmacol 22:1067-1075;2000.
16. Garbin F, Eckert K, Buttner P, Garbe C, Maurer HR. The influence of thymic preparation thymex-L on deficient antitumor activity of monocytes from melanoma patients in vitro. Oncol Rep 2:469;1995.
17. Gunzer M, Grabbe S. Dendritic cells in cancer immunotherapy. Crit Rev Immunol 21:133-145;2001.
18. Sodhi A, Gupta P. Study on pinocytosis and antigen presentation by murine peritoneal macrophages to T cells in vitro after cisplatin treatment. Arch Immunol Ther Exp (Warsz) 36:315-323;1988.
19. Hajek R, Butch AW. Dendritic cell biology and the application of dendritic cells to immunotherapy of multiple myeloma. Med Oncol 17:2-15;2000.
20. Hart D. Dendritic cells: unique leukocyte populations which control the primary immune response (review). Blood 90:3245-3287;1997.
21. Hodge JW, Rad AN, Grosenbach DW, Sabzevari H, Yafal AG, Gritz L, Schlom J. Enhanced activation of T cells by dendritic cells engineered to hyperexpress a triad of costimulatory molecules. J Natl Cancer Inst 92:1228-1239;2000.
22. Jalali A, Stoklosa T, Giermasz A, Olszewska D, Wilczynski G, Jakobisiak M, Golab J. A single injection of immature dendritic cells is able to induce antitumour response against a murine colon adenocarcinoma with a low apoptotic index. Oncol Rep 9:991-994;2002.
23. Johanne MK, Queendy Yu, Susan TP, Sarah EP, Srinivas S, Lisa AW, Bruce LR. Induction of antitumor immunity with dendritic cells transduced with adenovirus vector-encoding endogenous tumor-associated antigens. J Immunol 163:699-707;1999.
24. Kugler A, Stuhler G, Walden P, Zoller G, Zobywalski A, Brossart P, Trefzer U, Ullrich S, Muller CA, Becker B, Gross AJ, Hemmerleim B, Kanz L, Muller GA, Ringert RH. Regression of human metastatic renal cell carcinoma after vaccination with tumor cell-dendritic cell hybrids. Nat Med 6:332-336;2000.
25. 1 for chronic hepatitis C: the 48 weeks of treatment results. J Med Assoc Thai 84(suppl 1):S462-S468;2001.
26. Kumar A, Singh SM, Parajuli P. Modulatory effects of Dalton's lymphoma cells on the production of reactive nitrogen intermediates, IL-1 and TNF by murine peritoneal macrophages. Neoplasma 44:363;1994.
27. Labeur MS, Roters B, Pers B, Mehling A, Luger TA, Schwarz T, Grabbe S. Generation of tumor immunity by bone marrow-derived dendritic cells correlates with dendritic cell maturation stage. J Immunol 162:168-175;1999.
28. Lotze MT. Getting to the source: dendritic cells as therapeutic reagents for the treatment of patients with cancer. Ann Surg 226:1-5;1997.
29. Ludewig B, Barchiesi F, Pericin M, Zinkernagel RM, Hengartner H, Schwendener RA. In vivo antigen loading and activation of dendritic cells via a liposomal peptide vaccine mediates protective antiviral and anti-tumour immunity. Vaccine 19:23-32;2000.
30. Mayer G, Pohlmeyer K, Caliebe A, Heimueller E, Behnke B, Steimann G, Lange C, Beuth J. Low molecular thymic peptides stimulate human blood dendritic cells. Anticancer Res 5:2873-2883;2000.
31. Melero I, Vile RG, Colombo MP. Feeding dendritic cells with tumor antigens: self-service buffet or a la carte? Gene Ther 7:1167-1170;2000.
32. Mosmann T. Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays. J Immunol Methods 65:55-63;1983.
33. Nestle FO, Alijagic S, Gilliet M, Sun Y, Grabbe S, Dummer R, Burg G, Schadendorf D. Vaccination of melanoma patients with peptide- or tumor lysate-pulsed dendritic cells. Nat Med 4:328-332;1998.
34. Ohmori H, Kamo M, Yamakoshi K, Nitta MH, Hikida M, Kanayama N. Restoration of immunocyte functions by thymosin α1 in cyclophosphamide- induced immunodeficient mice. Immunopharmacol Immunotoxicol 23:75-82;2001.
35. Parajuli P, Singh SM. Ascitic growth of a T cell lymphoma in mice alters the humoral and cellular immune response to exogenous antigen. Tumor Biol 18:104-112;1997.
36. Parajuli P, Singh SM, Kumar A, Sodhi A. Alterations in the tumoricidal functions of murine tumor-associated macrophages during progressive growth of tumors in vivo. Cancer J 10:222-228;1997.
37. Sallusto F, Lanzavecchia A. Efficient presentation of soluble antigens by cultured human dendritic cells is maintained by granulocyte/macrophage colony-stimulating factor plus interleukin 4 and downregulated by tumor necrosis factor-α. J Exp Med 179:1109-1118:1994.
38. Schmitz M, Diestelkoetter P, Weigle B, Schmachtenberg F, Stevanovic S, Ockert D, Rammensee HG, Rieber EP. Generation of survivin-specific CD8+ T effector cells by dendritic cells pulsed with protein or selected peptides. Cancer Res 60:4845-4849;2000.
39. Shanker A, Singh SM. Immunopotentiation in mice bearing a transplantable T-cell lymphoma: role of thymic extract. Neoplasma 50:272-279;2003.
40. Shanker A, Singh SM, Sodhi A. Ascitic growth of a spontaneous T cell lymphoma induces thymic involution. 1. Alterations in the repertoire of CD4+/CD8+ thymocytes. Tumor Biol 21:288;2000.
41. Shanker A, Singh SM, Sodhi A. Ascitic growth of a spontaneous transplantable T cell lymphoma induces thymic involution. 2. Induction of apoptosis in thymocytes. Tumor Biol 21:315;2000.
42. Shanker A, Singh SM, Sodhi A. Impairment of T-cell functions with the progressive ascitic growth of a transplantable T-cell lymphoma of spontaneous origin. FEMS Immunol Med Microbiol 27:247-255;2000.
43. 1 on the production of nitric oxide by tumor-associated macrophages. Neoplasma 50:47-53;2003.